Pioglitazone

SKU: orb1310828

Description

Pioglitazone

Research Area

Cell Biology, Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 111025-46-8
• MW: 356.44
• Purity: 99.57%
• Formula: C₁₉H₂₀N₂O₃S
• SMILES: C(C1C(=O)NC(=O)S1)C2=CC=C(OCCC3=CC=C(CC)C=N3)C=C2
• Target: PPAR,Ferroptosis
• Solubility: 10% DMSO+90% Corn Oil:2 mg/mL (5.61 mM);DMSO:28.8 mg/mL (80.8 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  PPARδ (human):43 μM (EC50)|PPARγ (mouse):0.99 μM (EC50)|PPARα (mouse):100 μM (EC50)|PPARα (human):100 μM (EC50)|PPARγ (human):0.93 μM (EC50)
• In Vivo:
  METHODS: To investigat the effect of Pioglitazone on Insulin resistance, Pioglitazone (10 and 30 mg/kg) was orally administered to ob/ob and adipo-/-ob/ob mice once daily for 14 days. Results: Pioglitazone improves Insulin resistance and diabetes, which may be lipocalin-dependent in the liver but not in skeletal musclee. METHODS: To investigat the effect of Pioglitazone on cardiac remodeling, diabetic nephropathy rats were treated with oral administration of Pioglitazone (10 mg/kg) once daily for 4 weeks. Results: Pioglitazone significantly reduced body weight (BW), cardiac hypertrophy, elevated blood glucose levels, and related dyslipidemia.
• In Vitro:
  METHODS: HT-1080, MDA-MB-231, and PC-3 cells were treated with Pioglitazone for 3 days, and target cell toxicity was measured using MTT assay. Results: Pioglitazone did not affect cell growth at 100 μM.

Storage & Handling

• Storage: store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Pioglitazone, PPARγ, PPAR, Peroxisome proliferator-activated receptors, U72107, U-72107, U 72107, inhibit, ligand-binding, Ferroptosis, Inhibitor, diabete, domain, blood glucose

Compound Identifiers

PubChem CID

4829